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5-Lipoxygenase-activating protein (FLAP) is an 1 S-kDa integral membrane protein which is essential for cellular leukotriene (LT) synthesis, and 
is the target of LT biosynthesis inhibitors. However, the mechanism by which FLAP activates S-LO has not been determined. We have expressed 
high levels of human FLAP in Spodopteru frugiperda (39) insect cells infected with recombinant baculovirus, and used this system to demonstrate 
that FLAP specifically binds [‘2sI]L-739,059, a novel photoaffinity analog of arachidonic acid. This binding is inhibited by both arachidonic acid 
and MK-886, an LT biosynthesis inhibitor which specifically interacts with FLAP. These studies suggest hat FLAP may activate 5-LO by 
specifically binding arachidonic acid and transferring this substrate to the enzyme. 
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1. INTRODUCTION 
Leukotrienes are potent mediators of numerous bio- 
logical processes, including chemotaxis, vascular per- 
meability and smooth muscle contraction [1,2], and are 
implicated in the pathophysiology of various inflamma- 
tory and hypersensitivity disorders, including asthma 
and inflammatory bowel disease [3-51. As both the sol- 
uble enzyme 5-lipoxygenase (5-LO) and the integral 
membrane protein 5-lipoxygenase-activating protein 
(FLAP) are essential for the cellular synthesis of leuko- 
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~~~rev~ations~ 5-HPETE, (5~-hydro~roxy-6,8,11,14-eicosatetrae- 
noic acid; LT&, 5,6-oxido-7,9,1 l.l~eicosatetraenoi~ acid; LTB,, 
(5&12R)-dihydroxy-6,8,10,14-eicosatetraenoic acid; LTC,, (SS)-hy- 
droxy-(6R)-9glutathionyl-7,9,-(lrans)-l 1,14-(cis)-eicosatetraenoic 
acid; LTD,, (55’)-hydroxy-(6R)-9cysteinylglycyl-7.9-(rran~)-1l,l4- 
(cis)-eicosatetraenoic a id; LTE,, (S.S’)-hydroxy-(6R)-S-cysteinyl-7,9- 
(truns)- 11,14-(cis)-eicosatetraenoic ac d; 5-LO, 5-hpoxygenase; FLAP, 
5-lipoxygenase-activating protein; MK-886, 3-[I-@-chlorophenyl)-5- 
isopropyl-3-tert-butylthio-lH-indol-2-yl]-2,2-dimethylpropanoic acid 
(fo~erly desi~ated L-663,536); L-691,831, ((l-(4-iodo~n~l)-3-(3,3- 
dimethyl-l-oxo-l-butyl)-5-quinol-2-ylmethoxy)-indol-2-yl)-2,2-~met- 
hyl propionic acid; L-691,678, lo-indole-2-propanoic acid, 3-[(4- 
azidophenyl)sulfonyl]-2-[(4-iodophenyl)methyl]-~,~-dimethyl-5-(2- 
quinolinylmethoxy)-; DMSO, dimethyl sulphoxide; SDS-PAGE, so- 
dium dodecyl sulphate polyacrylamide gel electrophoresis; EDTA, 
ethylenediamine t traacetic acid; ICsO, concentratton required for 50% 
inhibition. 
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trienes [6], compounds which interact with these pro- 
teins are being developed as therapeutic agents. 
In response to a variety of agents which stimulate 
cellular LT synthesis, including calcium ionophore 
A23187 [7], thapsigargin IS], IgE [9], and fMLP [lo], 
5-LO translocates from the soluble to a membrane com- 
partment. The enzyme then catalyses both the oxygena- 
tion of arachidonic acid to 5-HPETE and the subse- 
quent conversion of S-HPETE to LTA, [11,12] which 
is the precursor of LTB, and the peptidoleukotrienes 
LTC4, LTD, and LTIE,. Compounds which specifically 
bind to FLAP, such as MK-886 [13,14] and MK-0591 
[15] inhibit this membrane association of 5-LO. While 
membrane association of 5-LO may be required for the 
efficient utilization of arachidonic acid, which is re- 
leased from membrane phospholipids by phospholi- 
pases, the critical role that FLAP plays in this process 
has not been determined. 
To assess whether FLAP specifically binds a sub- 
strate of 5-LO, we synthesized [‘251]L-739,059, a radi- 
oiodinated photoaffinity analog of arachidonic acid. 
This ligand specifically binds to human FLAP ex- 
pressed in Spodoptera frugiperda (WI) insect cells using 
recombinant baculovirus, with this binding being inhib- 
ited both by arachidonic acid and MK-886. These stud- 
ies suggest hat FLAP may activate 5-LO by specifically 
binding arachidonate and transferring this substrate to 
the enzyme for the concerted synthesis of LTA,. 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
Nucleotides and dNTPs were obtained from Boehringer Mannheim 
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(Montreal, Quebec, Canada). Restrtctton endonucleases, DNA 
polymerase I, Klenow fragment, T4 DNA hgase and T7 sequencing 
ktt were obtained from Pharmacia (Montreal, Quebec, Canada). Radi- 
oisotopes ‘2SI-Iabeled Protein A (IO mCi/mg) and [a-‘“P]dCTP (3,000 
Ci/mmol) were supplied by NEN-DuPont (Burlington. Ontario, Can- 
ada). The synthesis of [“51]L-739,059 will be described elsewhere. 
2.2. Cells and vwuses 
Escherichiu coli DH5a was obtained from Gibco/BRL and trans- 
formed according to published methods [16]. St9 msect cells were 
cultured in Grace’s complete medium (Gtbco/BRL) supplemented 
with 10% fetal bovine serum (Gibco/BRL), 50pgofgentamicin sulfate 
per ml, and 2.5 pg of amphotericm B (Fungizone) per ml in either 
Corning T flasks (Richmond Hill, Ontario, Canada) or spinner flasks 
(Bellco Glass, Inc., Vmeland, NJ) at 27°C following the procedures 
of Summers and Smith [17]. Sf9 insect cells and the pETL transfer 
vector were kindly provided by Dr. C.D. Richardson. Biotechnology 
Research Institute, Montreal, Quebec. Cell counts and cell viability 
were determined in 0.2% Trypan blue using a hemocytometer. 
2.3. Construction of recombinant transfer vector pETL-FLAP 
The human FLAP cDNA [6] was subcloned from the vector 
pBShFLAP [18] into the pETL transfer vector. Miniprep DNA from 
bacterial transformants was isolated, and the proper orientation of the 
inserted fragment with respect to the polyhedrm promoter was con- 
firmed by restriction digest and sequence analysts. The 11 -kb vector, 
pETL-FLAP, was purified usmg Magic Miniprep (Promega, Madi- 
son, WI) and subsequently used for co-transfectton with wild type 
baculovirus DNA. 
2.4. DNA transfections and plaque assaq’s 
Linearized wild type AcMNPV DNA (1 pg) (Invitrogen, San Diego, 
CA) was mixed with pETL-FLAP (2 pug) and co-transfected into St9 
cells by the calcium phosphate method [17]. After 4 days. cellular 
debris was removed by centrifugation at 1.000 x g for 5 min and the 
supernatant was used as the source of recombinant vtrus for the initial 
plaque assay. Plaque assays were carried out in culture dishes 
(100 x 15 mm) as previously described [19]. From this initial plaque 
assay, 10 blue plaques were subjected to dot blot analysis as previously 
described [19] and probed with a fragment of the human FLAP 
cDNA. Nine of the ten plaques which expressed B-galactosidase acttv- 
ity also contained the FLAP cDNA (data not shown). Pure recombi- 
nant virus was isolated from two of the FLAP-positive plaques. One 
of these isolates, designated rvFLAP600-9, was used to infect Sl9 cells 
(1.0-2.0 x lo6 cells/ml) at a multtplicity of infection of 10. 
2.5. Subceihdur fractionation 
Human polymorphonuclear leukocytes were prepared from buffy 
coat concentrates by dextran sedimentation and hypotonic lysis of 
contaminating red blood cells as previously described [20]. These 
membranes have previously been shown to contain FLAP [21]. Sf9 
cells were harvested by centrifugation (300 x g. 5 mitt, room tempera- 
ture) and washed with Dulbecco’s phosphate-buffered saline (D-PBS; 
GibcolBRL). Cell pellets were then sonicated in 15 mM Tris-HCl, pH 
7.5, 2 mM MgCl?, 0.3 mM EDTA, 1 mM phenylmethylsulfonyl fluo- 
ride at 4°C. and the 100,000 x g membrane fraction prepared as prevt- 
ously described [ 181. 
2.6. Protein wnmunoblottmg 
Protein samples were separated on 816% polyacrylamtde gels 
(Novex, San Diego, CA) m the presence of SDS and transferred to 
nitrocellulose overmght using the Western Transfer apparatus 
(Novex) according to the manufacturer’s instructions. Immunoblot 
analysis was performed as previously described [22], using a 1:200 
dilution of antiserum and [‘*‘I]Protein A (NEN-DuPont) as the detec- 
tion system. The rabbit polyclonal antiserum used for these studies IS 
designated H5 and recogmzes amino acid residues 41-52 of FLAP 
[23]. Protein concentrations were determined in mtcrotttre plates using 
Coomasste protein assay reagent (Pierce, Rockford, IL) according to 
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the manufacturer’s instructions, with bovine serum albumin as a 
standard. 
2.7. Radloligand binding assays 
Filter binding assays were performed with the quindole LT biosyn- 
thesis inhibitor [“‘I]L-691,831 as previously described (Charleson et 
al., 1992) using membrane preparations from Sl9 cells. Specific bind- 
ing in this assay is defined as the difference between the binding of 
[“51]L-691,831 to membranes in the absence and presence of MK-886 
at a concentration of 10 PM. 
2.8. Photoafjnity lubelrng und immunopreclprtation 
Photoaffinity labeling and tmmunoprecipitation of photoaffinity 
labeled protein were performed as previously described [23] using the 
quindole LT biosynthesis inhibitor [‘251]L691,678, or [‘*‘I]L-739,059. 
a photoaffinity analogue of arachtdonic actd. The rabbit polyclonal 
antiserum used for these studies is designated 709, and recognizes 
amino acid residues l-39 of FLAP [21]. 
3. RESULTS 
3.1. Expression of FLAP in Sfl insect cells 
Immunoblot analysis (Fig. 1) shows that while FLAP 
was undetectable in uninfected SI9 cells or SI9 cells 
infected with wild-type baculovirus, high levels of 
human FLAP were present in 100,000 x g membrane 









Fig. 1. Expression of human FLAP in SI9 cells. Expression of FLAP 
was assessed in 6 pug of a 100,000 x g membrane preparation from 
human leukocytes (lane 1) or 20,~g of 100,000 x g membrane prepara- 
tions from uninfected Sf9 cells (lane 2) St9 cells infected with wild-type 
baculovirus for 48 h (lane 3). or SI9 cells infected with rvFLAP600-9 
for 48 h (lane 4) by immunoblot analysis as described in section 2. 
Blots were exposed to X-ray film at -80°C for 60 min. The migration 
posittons of molecular weight markers are indicated. 
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rvFLAP600-9 for 48 h. FLAP was undetectable in the 
100,000 x g supernatant fraction of infected cells, sug- 
gesting that the protein is efficiently transferred to a 
membrane fraction when expressed in St9 insect cells. 
The maximal levels of FLAP obtained in membrane 
preparations of Sf9 cells were approximately 20-fold 
higher than those of human leukocyte preparations. 
tiserum and analyzed by SDS-PAGE (Fig. 2B). A single 
radiolabeled protein, corresponding to the migration 
position of FLAP, was immunoprecipitated. Labeling 
of this protein was inhibited by preincubation with MK- 
886. 
3.2. Specific binding of arachidonic acid to FLAP 
We next addressed whether FLAP expressed in St9 When membrane preparations of St9 cells infected 
cells specifically binds LT biosynthesis inhibitors. A ra- with rvFLAP600-9 and expressing high levels of FLAP 
dioligand binding assay for FLAP utilizing the inhibitor were labeled with [‘251]L-739,059, a photoaffinity ana- 
[‘251]L-691,831 has recently been developed [24]. Using log of arachidonic acid, and analyzed by SDS-PAGE, 
this assay, analysis of membrane preparations from Sf9 a radiolabeled species corresponding to the migration 
cells containing FLAP demonstrated saturable ligand position of FLAP was observed (Fig. 3). This radiola- 
binding, with specific binding representing at least 90% beled protein was not observed using membrane prepa- 
of total ligand binding at all protein concentrations an- rations from uninfected SI9 cells or membrane prepara- 
alyzed (Fig. 2A). No specific binding of [‘251]L-691,831 tions from infected cells which were boiled for 5 min 
was detectable using membrane preparations from un- prior to photolysis (data not shown). Photoaffinity la- 
infected Sl9 cells or to membrane preparations of cells beling of this protein was inhibited by arachidonic acid 
infected with wild-type baculovirus. To confirm that in a concentration-dependent manner, with an IC,, of 
FLAP expressed in Sf9 cells directly binds LT biosyn- lo-20 ,uM. The identity of this radiolabeled species as 
thesis inhibitors, membrane preparations from infected FLAP was confirmed by immunoprecipitation using a 
cells were labeled with the radioiodinated photoaffinity FLAP-specific antiserum (Fig. 3). Photoaffinity label- 
ligand [“‘I]L-691,678, an LT biosynthesis inhibitor ing of FLAP with [‘251]L-739,059 was also competed by 
which has previously been shown to covalently attach MK-886, but not by L-685,079 or L-671,480 (Fig. 3), 
to FLAP [23]. Following photoaffinity labeling, pro- indole and quinoline compounds which are only weak 
teins were immunoprecipitated with an anti-FLAP an- inhibitors of LT biosynthesis in human leukocytes [23]. 
b’ l 










Fig. 2. Binding of LT biosynthesis inhibitors to FLAP. Following infection of St9 cells with rvFLAP600-9 for 48 h, the binding of LT biosynthesis 
inhibitors to 100,000 x g membrane preparations was analyzed by radioligand binding analysis (A) or photoaffinity labeling (B). (A) Radioligand 
binding analysis of the indicated concentrations of a membrane preparation from St9 cells infected with rvFLAP600-9 for 48 h were performed 
using [‘*‘I]L-691,831 as described in section 2. (B) Membrane preparations from St9 cells infected with wild-type baculovirus for 48 h (lanes 1 and 
2), St9 cells infected with rvFLAP600-9 for 48 h (lanes 3 and 4) or human leukocytes (lanes 5 and 6) were photoaffinity labeled with [“‘I]L-691,678 
and immunoprecipitated with antiserum 709 as described in section 2. Immunoprecipitation was performed following photoaffinity labeling in the 
absence (lanes 1.3 and 5) or presence (lanes 2,4 and 6) of 1 PM MK-886. Samples were then separated by 13.5% SDS-PAGE and dried gels exposed 
to X-ray film for 3 days at -80°C. The migration positions of molecular weight markers are indicated. 
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Fig. 3. Photoaffinity labeling of FLAP with [?jL-739,059. The 
100,000 xg membrane fraction from St9 cells infected with 
rvFLAP600-9 for 48 h was photoaffinity-labeled with [“‘I]L-739,059 
(5061,000 Ci/mmol) as described in section 2, using 7.5 x lo5 cpm 
(lanes l-7) or 3 x 10’ cpm (lanes 8-l 1). Photoaffinity labeling was 
performed in the presence of DMSO vehicle (lanes 1, 6 and S), ara- 
chidonic acid at a con~ntration of 1 pM (lane 21, 10 PM (tane 3),25 
pM (lane 4), or 50 pM (lane 5), 1 PM MK-886 (lanes 7 and 9). 1 PM 
L-685,079 (lane 10) or 1 FM L-671.480 (lane 11). For samples l-5 and 
8811, 50 fig of protein was labeled. For samples 6 and 7. 300 pg of 
protein was labeled and these samples were immunoprecipitated using 
antiserum 709, as described in section 2. Samples were separated by 
13.5% SDS-PAGE, and dried gels exposed to X-ray film for 3 days 
at -80°C. The migration positions of molecular weight markers are 
indicated. The structure of [‘251]L-739,059 is shown. 
4. DISCUSSION 
In recent years it has been demonstrated that FLAP 
plays an essential role in the cellular synthesis of LTs 
and represents a suitable target for LT biosynthesis in- 
hibitors. However, the specific role that FLAP plays in 
LT biosynthesis has not been determined. In the present 
study we describe the first high level expression of 
FLAP, using the recombinant baculovirus rvFLAP600- 
9 to generate levels of human FLAP in Sf9 insect cells 
which are approximately 20-fold higher than those pres- 
ent in human leukocytes. FLAP which is incorporated 
into membranes of Sf9 cells can specifically bind LT 
biosynthesis inhibitors, as determined by a noncovalent 
radioligand binding assay as well as by i~unoprecip- 
itation of FLAP to which the radioiodinated pho- 
toaffinity ligand [‘*‘I]L-69 1,678 is bound. Thus, the Sf9 
expression system provides a rich source of FLAP for 
studies to analyze both the function and inhibitor bind- 
ing characteristics of the protein. 
We have used Sf9 cell membranes containing human 
FLAP in conjunction with [1251]L-739,059, a novel pho- 
toaffinity analog of arachidonate, to demonstrate that 
FLAP specifically binds arachidonic acid, and that this 
binding is competed by the LT biosynthesis inhibitor 
MK-886. Interestingly, the I& for inhibition of 
[“51]L-739,059 binding to FLAP by arachidonic acid 
(10-20 PM) is similar to the K,,, for arachidonic acid 
determined for 5-LO from porcine [25] and human [26] 
leukocytes. The demonstration that FLAP specifically 
binds arachidonic acid suggests that FLAP may acti- 
vate 5-LO by binding and transferring this substrate to 
the enzyme for the concerted synthesis of LTA,. Consis- 
tent with this hypothesis, exogenous arachidonate in- 
creases levels of LT synthesis in human leukocytes, and 
this synthesis remains FLAP-dependent as it is inhibited 
by MK-886 [27]. 
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